Targeted alpha therapy (astatine At-211) for cancer treatment
| Date | Round | Amount |
|---|---|---|
| Oct 2024 | Series B Alpha Fusion, an astatine targeted-alpha-therapy startup, raised 1.02B JPY in Series B co-led by SBI Investment and Osaka University VC, with Mitsui Mining & Smelting, Kobe University Capital and Joyo Capital Partners as new investors. | $6.7M |